Eurofins Strengthens Its Clinical Diagnostic Footprint in France with the Acquisition of 4 Laboratories Year to Date
May 09 2017 - 4:14AM
Business Wire
Regulatory News:
Eurofins Scientific (Paris:ERF) (EUFI.PA), a global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces that it has acquired four clinical laboratories
in France since the beginning of 2017, as part of the Group’s
strategy to strengthen its footprint in clinical diagnostics to
better serve the healthcare industry in the country.
The Group acquired iLab in Provence-Alpes-Côte d'Azur and
Biosphere in Rhône-Alpes, consolidating the Group’s footprint in
these regions. In addition, the Group has also acquired two groups
of laboratories in Marseille and Martigues, both focused on
specialty clinical testing. The 4 laboratories have combined annual
revenues in excess of EUR 10m.
The acquisitions are consistent with Eurofins’ strategy to
strengthen its market position in the core regions of France, and
to further develop as a national player with strong local
footprint.
Comment from Dr. Gilles Martin, Eurofins CEO: “These
transactions demonstrate Eurofins’ commitment to developing its
clinical diagnostics platform, which should enable the Group to
continue deploying its technical know-how and proprietary
technologies, including its competencies in specialty diagnostic
testing, in France and throughout the rest of Europe.”
For more information, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170509005736/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024